The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)

John C. Byrd

Division of Hematology and Oncology

Comprehensive Cancer Center

The Ohio State University

Columbus 43210-1240



Name/email consistency: high



  • Division of Hematology and Oncology, Comprehensive Cancer Center, The Ohio State University, Columbus 43210-1240, USA. 2002 - 2006
  • Department of Internal Medicine, Division of Hematology-Oncology, Starling Loving Hall, Rm 302, USA. 2005
  • Division of Hematology-Oncology, Walter Reed Army Medical Center, Washington, USA. 2001 - 2003
  • Department of Medicine, The Ohio State University, Columbus, OH 43210, USA. 2003


  1. Treatment of relapsed chronic lymphocytic leukemia: old and new therapies. Byrd, J.C., Lin, T.S., Grever, M.R. Semin. Oncol. (2006) [Pubmed]
  2. A phase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia. Byrd, J.C., Marcucci, G., Parthun, M.R., Xiao, J.J., Klisovic, R.B., Moran, M., Lin, T.S., Liu, S., Sklenar, A.R., Davis, M.E., Lucas, D.M., Fischer, B., Shank, R., Tejaswi, S.L., Binkley, P., Wright, J., Chan, K.K., Grever, M.R. Blood (2005) [Pubmed]
  3. Treatment of relapsed chronic lymphocytic leukemia by 72-hour continuous infusion or 1-hour bolus infusion of flavopiridol: results from Cancer and Leukemia Group B study 19805. Byrd, J.C., Peterson, B.L., Gabrilove, J., Odenike, O.M., Grever, M.R., Rai, K., Larson, R.A. Clin. Cancer Res. (2005) [Pubmed]
  4. Repetitive cycles of high-dose cytarabine benefit patients with acute myeloid leukemia and inv(16)(p13q22) or t(16;16)(p13;q22): results from CALGB 8461. Byrd, J.C., Ruppert, A.S., Mrózek, K., Carroll, A.J., Edwards, C.G., Arthur, D.C., Pettenati, M.J., Stamberg, J., Koduru, P.R., Moore, J.O., Mayer, R.J., Davey, F.R., Larson, R.A., Bloomfield, C.D. J. Clin. Oncol. (2004) [Pubmed]
  5. Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712). Byrd, J.C., Peterson, B.L., Morrison, V.A., Park, K., Jacobson, R., Hoke, E., Vardiman, J.W., Rai, K., Schiffer, C.A., Larson, R.A. Blood (2003) [Pubmed]
  6. Interphase cytogenetic abnormalities in chronic lymphocytic leukemia may predict response to rituximab. Byrd, J.C., Smith, L., Hackbarth, M.L., Flinn, I.W., Young, D., Proffitt, J.H., Heerema, N.A. Cancer Res. (2003) [Pubmed]
  7. KRN5500: a novel therapeutic agent with in vitro activity against human B-cell chronic lymphocytic leukemia cells mediates cytotoxicity via the intrinsic pathway of apoptosis. Byrd, J.C., Lucas, D.M., Mone, A.P., Kitner, J.B., Drabick, J.J., Grever, M.R. Blood (2003) [Pubmed]
  8. Apoptotic-regulatory and complement-protecting protein expression in chronic lymphocytic leukemia: relationship to in vivo rituximab resistance. Bannerji, R., Kitada, S., Flinn, I.W., Pearson, M., Young, D., Reed, J.C., Byrd, J.C. J. Clin. Oncol. (2003) [Pubmed]
  9. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Byrd, J.C., Mrózek, K., Dodge, R.K., Carroll, A.J., Edwards, C.G., Arthur, D.C., Pettenati, M.J., Patil, S.R., Rao, K.W., Watson, M.S., Koduru, P.R., Moore, J.O., Stone, R.M., Mayer, R.J., Feldman, E.J., Davey, F.R., Schiffer, C.A., Larson, R.A., Bloomfield, C.D. Blood (2002) [Pubmed]
  10. UCN-01 induces cytotoxicity toward human CLL cells through a p53-independent mechanism. Byrd, J.C., Shinn, C., Willis, C.R., Flinn, I.W., Lehman, T., Sausville, E., Lucas, D., Grever, M.R. Exp. Hematol. (2001) [Pubmed]
WikiGenes - Universities